Novartis wins new EU approval for Afinitor; Pfizer's tender offer for Icagen succeeds;

@FiercePharma: Biogen takes over marketing JVs that had been selling its MS meds Avonex, Tysabri in 29 countries. Article $BIIB | Follow @FiercePharma

> European regulators approved Novartis' ($NOVN) mTOR inhibitor Afinitor for a rare type of pancreatic cancer on the heels of FDA's nod for the same use. Article

> Pfizer ($PFE) wrapped up its tender offer for Icagen, ending with 54% of the North Carolina-based biopharma, announced a bid of $6 per share to minority shareholders, beginning Sept. 12. News

> San Diego law enforcement officials confirmed a determination of suicide in the death of Medicis Pharmaeutical ($MRX) CEO Jonah Shacknai's girlfriend. Report

> Berlin Pharmaceutical inked a deal to market a range of Swiss-based Acino Pharma's current and future products in Thailand. News

> Drugmaker logos will continue to appear in disclosures of corporate support for continuing education, the Accreditation Council for Continuing Medical Education decided following a mixed reaction to a proposed logo ban. Item

> Eisai is launching two more over-the-counter products in its Selbelle line of stomach drugs. Piece

> Hikma Pharmaceuticals launched its version of the heparin blood thinner in U.S. in single- and multi-use vials. Article

> The British animal health firm Dechra Pharmaeuticals saw increasing sales of branded products lift profits by 15% during the past year. Article

> New Hampshire passes law to allow pharmacists to give vaccines against pneumonia and shingles, as well as seasonal flu. Story

Biotech News

@FierceBiotech: Fierce 15 is now live! See the 15 outstanding private biotechs we've selected this year. Report | Follow @FierceBiotech

@JohnCFierce: One of my favorites is RJ Kirk/Intrexon talking about what he likes in a partner and why he won't work with Big Pharma. Piece | Follow @JohnCFierce

@RyanMFierce: Researchers use neural stem cells (of iPS variety) to study impacts of potential bipolar-disorder treatments. Item | Follow @RyanMFierce

> FDA review drops a bombshell on Bayer, J&J anti-clotting drug Xarelto. More

> Sanofi singles out top pipeline prospects, new cost cuts. News

> Vertex tracks encouraging IIa data for JAK3 rheumatoid arthritis drug. Report

Biotech IT News

> Merck taps Zymeworks' high-tech antibody shop in $187M deal. News

> Facebook app shows how people swap germs. Piece

> Glencoe, Aridhia team to develop life sciences tech. Story

> Impact Corelab sprouts with clinical tech from Radiant Sage. Piece

> Social networking rallies volunteers in Mayo Clinic study. Story

> MedNet seeks funds to compete in EDC game. Item

Manufacturing News

> Abbott exec tapped for H&P manuf. ops. Report

> Lilly looks eastward with generics deal. Article

> Pharma deal-making minimizes manufacturing. Item

> No penalties for stunning gray price hikes on cancer, anesthesia drugs. Story

> GSK sees resistance to wind turbine project. More

> Vax maker CSL on road to GMP compliance. Article

Biotech Research News

> Researchers find new target for PTSD treatment. Read more

> New drug-discovery center lost in translation. Article

> Researchers report promising new TB vaccine. News

> Stem cells open new front against bipolar disorder. More

> Pimple treatments pocked with poor supporting science. Item

> Get fat stem cells talking to follicles and up sprouts hair. Story

And Finally... Menopause may not be the culprit in women's increasing heart risks. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.